Streetbeat News

Analyst Ratings

MDNA

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Medicenna Therapeutics (NASDAQ:MDNA) and maintained a price target of $2.5.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:46 am

HARP

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Harpoon Therapeutics (NASDAQ:HARP) and maintained a price target of $4.5.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:46 am

ECOR

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on electroCore (NASDAQ:ECOR) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:45 am

RWLK

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on ReWalk Robotics (NASDAQ:RWLK) and maintained a $3 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:43 am

PGEN

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Precigen (NASDAQ:PGEN) and maintained a $6 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:42 am

AVDL

HC Wainwright & Co. analyst Oren Livnat has reiterated a 'Buy' rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintained a price target of $21.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:41 am

ZNTL

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Zentalis Pharma (NASDAQ:ZNTL) and maintained a $55 price target.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:40 am

INFN

Needham analyst Alex Henderson maintains a Strong Buy rating on Infinera (NASDAQ:INFN), but has lowered the price target from $15 to $10.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:39 am

FNV

HC Wainwright & Co. analyst Heiko Ihle maintains a Buy rating on Franco-Nevada (NYSE:FNV) and raises the price target from $180 to $185.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:36 am

LUMO

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Lumos Pharma (NASDAQ:LUMO) and maintained a price target of $28.

Portfolio Pulse from richadhand@benzinga.com

August 10, 2023 | 10:35 am